Robert H. Gruninger

893 total citations
14 papers, 704 citations indexed

About

Robert H. Gruninger is a scholar working on Oncology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert H. Gruninger has authored 14 papers receiving a total of 704 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Organic Chemistry and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert H. Gruninger's work include Cancer-related Molecular Pathways (5 papers), Angiogenesis and VEGF in Cancer (4 papers) and HER2/EGFR in Cancer Research (4 papers). Robert H. Gruninger is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), Angiogenesis and VEGF in Cancer (4 papers) and HER2/EGFR in Cancer Research (4 papers). Robert H. Gruninger collaborates with scholars based in United States, United Kingdom and Japan. Robert H. Gruninger's co-authors include Steven A. Middleton, Stuart L. Emanuel, Peter J. Connolly, Angel R. Fuentes‐Pesquera, Linda K. Jolliffe, Ronghui Lin, Catherine A. Rugg, Steven K. Wetter, William V. Murray and Mary Adams and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Robert H. Gruninger

14 papers receiving 693 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert H. Gruninger United States 13 345 252 234 79 74 14 704
Angel R. Fuentes‐Pesquera United States 14 561 1.6× 274 1.1× 261 1.1× 89 1.1× 82 1.1× 16 888
André Richters Germany 17 212 0.6× 480 1.9× 144 0.6× 65 0.8× 44 0.6× 24 776
Mauro Angiolini Italy 10 247 0.7× 387 1.5× 139 0.6× 94 1.2× 45 0.6× 14 587
Karen L. Milkiewicz United States 14 266 0.8× 384 1.5× 281 1.2× 62 0.8× 37 0.5× 19 649
Arwin Aban United States 9 211 0.6× 575 2.3× 165 0.7× 66 0.8× 48 0.6× 13 748
Pascal Furet Switzerland 7 189 0.5× 397 1.6× 247 1.1× 60 0.8× 41 0.6× 7 565
Rémy Morgentin France 13 301 0.9× 292 1.2× 173 0.7× 51 0.6× 58 0.8× 23 624
Bernard Barlaam United Kingdom 17 306 0.9× 448 1.8× 256 1.1× 51 0.6× 101 1.4× 40 811
Kimberly G. Petrov United States 8 277 0.8× 288 1.1× 181 0.8× 79 1.0× 50 0.7× 9 588
Keith R. Hornberger United States 15 405 1.2× 805 3.2× 371 1.6× 88 1.1× 51 0.7× 18 1.2k

Countries citing papers authored by Robert H. Gruninger

Since Specialization
Citations

This map shows the geographic impact of Robert H. Gruninger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert H. Gruninger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert H. Gruninger more than expected).

Fields of papers citing papers by Robert H. Gruninger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert H. Gruninger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert H. Gruninger. The network helps show where Robert H. Gruninger may publish in the future.

Co-authorship network of co-authors of Robert H. Gruninger

This figure shows the co-authorship network connecting the top 25 collaborators of Robert H. Gruninger. A scholar is included among the top collaborators of Robert H. Gruninger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert H. Gruninger. Robert H. Gruninger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Xu, Guozhang, Terry V. Hughes, Peter J. Connolly, et al.. (2008). Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 18(12). 3495–3499. 48 indexed citations
2.
Xu, Guozhang, M.C. Abad, Peter J. Connolly, et al.. (2008). 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(16). 4615–4619. 80 indexed citations
3.
Huang, Shenlin, Ronghua Li, Peter J. Connolly, et al.. (2007). Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1). Bioorganic & Medicinal Chemistry Letters. 17(8). 2179–2183. 11 indexed citations
4.
Emanuel, Stuart L., Terry V. Hughes, Mary Adams, et al.. (2007). Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors. Molecular Pharmacology. 73(2). 338–348. 30 indexed citations
5.
Lin, Ronghui, Peter J. Connolly, Yanhua Lü, et al.. (2007). Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents. Bioorganic & Medicinal Chemistry Letters. 17(15). 4297–4302. 75 indexed citations
6.
Hughes, Terry V., Stuart L. Emanuel, Steven K. Wetter, et al.. (2007). 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry Letters. 17(12). 3266–3270. 40 indexed citations
7.
Lin, Ronghui, Yanhua Lü, Steven K. Wetter, et al.. (2005). 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation. Bioorganic & Medicinal Chemistry Letters. 15(9). 2221–2224. 21 indexed citations
8.
Kuo, Gee‐Hong, Catherine Prouty, Aihua Wang, et al.. (2005). Synthesis and Structure−Activity Relationships of Pyrazine-Pyridine Biheteroaryls as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors. Journal of Medicinal Chemistry. 48(15). 4892–4909. 30 indexed citations
9.
Emanuel, Stuart L., Catherine A. Rugg, Robert H. Gruninger, et al.. (2005). The In vitro and In vivo Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases. Cancer Research. 65(19). 9038–9046. 101 indexed citations
10.
Kuo, Gee‐Hong, Stuart L. Emanuel, Aihua Wang, et al.. (2005). Synthesis and Identification of [1,3,5]Triazine-pyridine Biheteroaryl as a Novel Series of Potent Cyclin-Dependent Kinase Inhibitors. Journal of Medicinal Chemistry. 48(14). 4535–4546. 72 indexed citations
11.
Lin, Ronghui, Peter J. Connolly, Shenlin Huang, et al.. (2005). 1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogues as Novel and Potent Anticancer Cyclin-Dependent Kinase Inhibitors:  Synthesis and Evaluation of Biological Activities. Journal of Medicinal Chemistry. 48(13). 4208–4211. 109 indexed citations
12.
Kuo, Gee‐Hong, Aihua Wang, Stuart L. Emanuel, et al.. (2004). Synthesis and Discovery of Pyrazine−Pyridine Biheteroaryl as a Novel Series of Potent Vascular Endothelial Growth Factor Receptor-2 Inhibitors. Journal of Medicinal Chemistry. 48(6). 1886–1900. 24 indexed citations
13.
Barbone, Francis P., Steven A. Middleton, Dana L. Johnson, et al.. (1997). Mutagenesis Studies of the Human Erythropoietin Receptor. Journal of Biological Chemistry. 272(8). 4985–4992. 14 indexed citations
14.
Middleton, Steven A., Dana L. Johnson, Frank J. McMahon, et al.. (1996). Identification of a Critical Ligand Binding Determinant of the Human Erythropoietin Receptor. Journal of Biological Chemistry. 271(24). 14045–14054. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angel R. Fuentes‐Pesquera Breakdown of academic impact, for papers by André Richters Breakdown of academic impact, for papers by Mauro Angiolini Breakdown of academic impact, for papers by Karen L. Milkiewicz Breakdown of academic impact, for papers by Arwin Aban Breakdown of academic impact, for papers by Pascal Furet Breakdown of academic impact, for papers by Rémy Morgentin Breakdown of academic impact, for papers by Bernard Barlaam Breakdown of academic impact, for papers by Kimberly G. Petrov Breakdown of academic impact, for papers by Keith R. Hornberger
Rankless by CCL
2026